StockChartsAI.com
All Chart Prices Delayed at least 15 minutesBefore accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Stock Charts AI Power Rank: 9.0
Power Rank trend -> Rising
07/26/2024 16:00:00 EST
CureVac NV (CVAC)
Industry: Biotechnology
Follow @stockchartsai on TwitterPrice Support Resistance
In the past 20 trading days, CVAC has been trading in a range between $3.79 and $3.06 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
CVAC is trading between resistance at $3.79 about 2% to the upside and support at $3.43 -8% to the downside. If it can break above the resistance, it could have some more upside to the next line of resistance at $6.12, about a 65% move. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Upside / Downside Potential
CureVac NV $CVAC entered a Green zone 10 days ago on the AI powered stock chart. Wall Street analysts have an AVG target price $14.91, a potential upside of 300.81% from the recent price of 3.72. The stock is trading 172.58% (potential upside) below its 52 week high of $10.14 and 68.33 % (potential downside) above its 52 week low of $2.21 - based on the recent price.
Company Summary
CureVac NV. , a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
News
| CureVac (CVAC) Upgraded to Buy: What Does It Mean for the Stock? CureVac (CVAC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. Source: Zacks Investment Research Mon, 15 Jul 2024 13:01:36 -0400 Sentiment: Positive |
| CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent litigation UK trial on validity of intellectual property rights EP 3 708 668 B1 and EP 4 023 755 B1 (split poly-A tail technology) began July 10; judgement expected later in 2024 TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 11, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the latest trial dates for its ongoing patent litigation against Pfizer/BioNTech in multiple geographies including the U.S., UK and Germany. Source: Accesswire Thu, 11 Jul 2024 07:15:00 -0400 Sentiment: Neutral |
| Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer ANTWERP, Belgium--(BUSINESS WIRE)--Agomab Therapeutics NV (‘Agomab') today announced that Pierre Kemula will join the company as Chief Financial Officer (CFO) effective November 1, 2024, bringing more than 15 years of experience in global biotech financial leadership. Mr. Kemula joins Agomab from CureVac N.V. (Nasdaq: CVAC), where he currently serves as CFO. In this role, Mr. Kemula has led CureVac's financial and capital markets activities since 2016, characterized by a successful listing on N. Source: Business Wire Thu, 11 Jul 2024 07:00:00 -0400 Sentiment: Neutral |
| CureVac Layoffs 2024: What to Know About the Latest CVAC Job Cuts CureVac (NASDAQ: CVAC ) layoffs are coming for the vaccine maker's employees as it prepares to undergo a restructuring to streamline its business. CureVac has announced that its layoffs will affect 30% of its global workforce. Source: InvestorPlace Wed, 03 Jul 2024 11:49:34 -0400 Sentiment: Negative |
| GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines The deal represents a vote of confidence in the future of the mRNA-based vaccine market. Source: Barrons Wed, 03 Jul 2024 10:18:00 -0400 Sentiment: Positive |
Technicals 52 Week Hi: 10.14 52 Week Low: 2.215 Beta: 2.636 50 Day MA: 3.6379 200 Day MA: 3.9614 Earnings / Revenue Trends Qtr Earnings Growth YOY: 0 Qtr Revenue Growth YOY: 0.736 Forward PE: 9.1659 Trailing PE: 0